Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • 3 hours ago

ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • 21 hours ago

ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated Year-End 2025 Cash Grew to Approximately $88 Million with an Unaudited Operating Cash Flow Estimate of ~$40 Million in 4Q 2025 2026 Expected to be ADMA's First Full Year of Yield-Enhanced Production, Supporting Anticipated Sustained Margin Expansion Strategic Plasma Network Repositioning Expected to Enhance Margins and Strengthen Long-Term Supply Visibility Positive, Statistically Significant Real-World ASCENIV™ Outcomes to be Presented at CIS in May 2026; Additional ASCENIV Data Expected Throughout 2026 Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Submission in 2026 Ongoing Share Repurchases and Capital Structure Strengthening to Enhance Stockholder Value FY 2026 and FY 2027 Revenue Expected to be Approximately $635 Million and $775 Million, Respectively FY 2026 and FY 2027 Adjusted Net Income Expected to be Approximately $255 Million and $315 Million, Respectively FY 2026 and FY 2027 Adjusted EBITDA Expected to be Approximately $360 Million and $455 Million, Respectively ADMA Targets Greater Than $1.1 Billion in Annual Revenue in FY 2029, Representing ~20% CAGR(3) ADMA Targets Greater Than $700 Million in Adjusted EBITDA in FY 2029, Representing ~30% CAGR RAMSEY, N.J. and BOCA RATON, Fla.

GlobeNewsWire • Jan 12, 2026

Why Adma Biologics (ADMA) Outpaced the Stock Market Today

In the most recent trading session, Adma Biologics (ADMA) closed at $18.34, indicating a +1.72% shift from the previous trading day.

Zacks Investment Research • Jan 6, 2026

ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.

GlobeNewsWire • Jan 5, 2026

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 12, 2025

Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Dec 1, 2025

Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet

The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 27, 2025

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.

Zacks Investment Research • Nov 25, 2025